Bristol-Myers Squibb: Building Billion-Dollar Device Businesses
Focusing on franchises not individual products, BMS is developing strategies for its Zimmer and ConvaTec divisions that enable them to grow at once independently and synergistically. BMS is exploring potential links between its various businesses which capitalize on new market or technology opportunities without sacrificing the skills that made each company successful.
You may also be interested in...
US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.
But advisory committee members caution against including pediatric population in COVID-19 vaccine trials, and one member expresses concern that Pfizer is testing those as young as 12 years of age. Agency is in discussions with product sponsors about enrollment of adolescents.
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.